Literature DB >> 25644186

Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.

Julie K Heimbach1, Ryutaro Hirose, Peter G Stock, David P Schladt, Hui Xiong, Jiannong Liu, Kim M Olthoff, Ann Harper, Jon J Snyder, Ajay K Israni, Bertram L Kasiske, W Ray Kim.   

Abstract

UNLABELLED: The current system granting liver transplant candidates with hepatocellular carcinoma (HCC) additional Model for End-Stage Liver Disease (MELD) points is controversial due to geographic disparity and uncertainty regarding optimal prioritization of candidates. The current national policy assigns a MELD exception score of 22 immediately upon listing of eligible patients with HCC. The aim of this study was to evaluate the potential effects of delays in granting these exception points on transplant rates for HCC and non-HCC patients. We used Scientific Registry of Transplant Recipients data and liver simulated allocation modeling software and modeled (1) a 3-month delay before granting a MELD exception score of 25, (2) a 6-month delay before granting a score of 28, and (3) a 9-month delay before granting a score of 29. Of all candidates waitlisted between January 1 and December 31, 2010 (n = 28,053), 2773 (9.9%) had an HCC MELD exception. For HCC candidates, transplant rates would be 108.7, 65.0, 44.2, and 33.6 per 100 person-years for the current policy and for 3-, 6-, and 9-month delays, respectively. Corresponding rates would be 30.1, 32.5, 33.9, and 34.8 for non-HCC candidates.
CONCLUSION: A delay of 6-9 months would eliminate the geographic variability in the discrepancy between HCC and non-HCC transplant rates under current policy and may allow for more equal access to transplant for all candidates.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25644186      PMCID: PMC4547840          DOI: 10.1002/hep.27704

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

1.  Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula.

Authors:  Richard B Freeman; Robert G Gish; Ann Harper; Gary L Davis; John Vierling; Leslie Lieblein; Goran Klintmalm; Jamie Blazek; Robert Hunter; Jeffrey Punch
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

Review 2.  Scientific Registry of Transplant Recipients: collecting, analyzing, and reporting data on transplantation in the United States.

Authors:  Susan Leppke; Tabitha Leighton; David Zaun; Shu-Cheng Chen; Melissa Skeans; Ajay K Israni; Jon J Snyder; Bertram L Kasiske
Journal:  Transplant Rev (Orlando)       Date:  2013-03-06       Impact factor: 3.943

3.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

4.  Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation.

Authors:  P Sharma; A M Harper; J L Hernandez; T Heffron; D C Mulligan; R H Wiesner; V Balan
Journal:  Am J Transplant       Date:  2006-06-09       Impact factor: 8.086

5.  Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.

Authors:  Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton
Journal:  Liver Transpl       Date:  2006-08       Impact factor: 5.799

6.  MELD Exceptions and Rates of Waiting List Outcomes.

Authors:  A B Massie; B Caffo; S E Gentry; E C Hall; D A Axelrod; K L Lentine; M A Schnitzler; A Gheorghian; P R Salvalaggio; D L Segev
Journal:  Am J Transplant       Date:  2011-09-15       Impact factor: 8.086

7.  Magnitude of change in alpha-fetoprotein in response to transarterial chemoembolization predicts survival in patients undergoing liver transplantation for hepatocellular carcinoma.

Authors:  M Bhat; M Hassanain; E Simoneau; G N Tzimas; P Chaudhury; M Deschenes; D Valenti; P Ghali; P Wong; T Cabrera; J Barkun; J I Tchervenkov; P Metrakos
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

Review 8.  Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy.

Authors:  Russell H Wiesner; Richard B Freeman; David C Mulligan
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

9.  How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?

Authors:  Gerd Otto; Marcus Schuchmann; Maria Hoppe-Lotichius; Michael Heise; Arndt Weinmann; Torsten Hansen; Michael P Pitton
Journal:  J Hepatol       Date:  2013-04-12       Impact factor: 25.083

10.  Evolving frequency and outcomes of liver transplantation based on etiology of liver disease.

Authors:  Ashwani K Singal; Praveen Guturu; Bashar Hmoud; Yong-Fang Kuo; Habeeb Salameh; Russell H Wiesner
Journal:  Transplantation       Date:  2013-03-15       Impact factor: 4.939

View more
  33 in total

1.  Transplantation: Allocation of liver transplants-a road to consensus.

Authors:  John P Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-27       Impact factor: 46.802

2.  Geographic Disparity in Deceased Donor Liver Transplant Rates Following Share 35.

Authors:  Mary G Bowring; Sheng Zhou; Eric K H Chow; Allan B Massie; Dorry L Segev; Sommer E Gentry
Journal:  Transplantation       Date:  2019-10       Impact factor: 4.939

3.  Twenty years of Milan criteria and live-donor liver transplantation in the US: a contrast in transparency, regulation, and expectation.

Authors:  David C Cronin; Timothy M Cronin
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

Review 4.  Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.

Authors:  Nicole E Rich; Neehar D Parikh; Amit G Singal
Journal:  Curr Treat Options Gastroenterol       Date:  2017-06

Review 5.  Liver Allocation Policies in the USA: Past, Present, and the Future.

Authors:  Anjana Pillai; Thomas Couri; Michael Charlton
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

6.  Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.

Authors:  Andrew C Gordon; Ahmed Gabr; Ahsun Riaz; Omar M Uddin; Nadine Abouchaleh; Rehan Ali; Joseph Kallini; Riad Salem; Robert J Lewandowski
Journal:  Cardiovasc Intervent Radiol       Date:  2018-06-12       Impact factor: 2.740

7.  Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.

Authors:  Tanveen Ishaque; Allan B Massie; Mary G Bowring; Christine E Haugen; Jessica M Ruck; Samantha E Halpern; Madeleine M Waldram; Macey L Henderson; Jacqueline M Garonzik Wang; Andrew M Cameron; Benjamin Philosophe; Shane Ottmann; Anne F Rositch; Dorry L Segev
Journal:  Am J Transplant       Date:  2018-11-09       Impact factor: 8.086

Review 8.  Treatment Options for Early-Stage Hepatocellular Carcinoma.

Authors:  Nora E Tabori; Gajan Sivananthan
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

9.  Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Authors:  Ashil J Gosalia; Paul Martin; Patricia D Jones
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

10.  Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation.

Authors:  Theodore H Welling; Kevin Eddinger; Kristen Carrier; Danting Zhu; Tyler Kleaveland; Derek E Moore; Douglas E Schaubel; Peter L Abt
Journal:  Liver Transpl       Date:  2018-09       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.